These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 24581673)

  • 41. FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.
    Flamme I; Ellinghaus P; Urrego D; Krüger T
    PLoS One; 2017; 12(10):e0186979. PubMed ID: 29073196
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) on anemia in non-dialysis-dependent chronic kidney disease (NDD-CKD): a systematic review and meta-analysis.
    Zhang S; Guo J; Xie S; Chen J; Yu S; Yu Y
    Int Urol Nephrol; 2021 Jun; 53(6):1139-1147. PubMed ID: 33026571
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease.
    Sugahara M; Tanaka T; Nangaku M
    Kidney Int; 2017 Aug; 92(2):306-312. PubMed ID: 28651951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prolyl-hydroxylase inhibitors for the treatment of anemia in chronic kidney disease.
    McMahon GM; Singh AK
    Curr Opin Nephrol Hypertens; 2019 Nov; 28(6):600-606. PubMed ID: 31567284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Not Available].
    Aniort J; Greze C; Kosmadakis G
    Nephrol Ther; 2022 Dec; 18(6S1):6S25-6S32. PubMed ID: 36585122
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Discovery of novel 2-[(4-hydroxy-6-oxo-2,3-dihydro-1H-pyridine-5-carbonyl)amino]acetic acid derivatives as HIF prolyl hydroxylase inhibitors for treatment of renal anemia.
    Hamada M; Takayama T; Shibata T; Hiratate A; Takahashi M; Yashiro M; Takayama N; Okumura-Kitajima L; Koretsune H; Kajiyama H; Naruse T; Kato S; Takano H; Kakinuma H
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1725-1730. PubMed ID: 29681433
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
    Qureshi IZ; Abid K; Ambreen F; Qureshi AL
    Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pediatric uses of recombinant human erythropoietin: the outlook in 1991.
    Alexander SR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):42-53. PubMed ID: 1928079
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cell-based therapies for the treatment of critical limb ischemia.
    HoWangYin KY; Loinard C; Bakker W; Guérin CL; Vilar J; d'Audigier C; Mauge L; Bruneval P; Emmerich J; Lévy BI; Pouysségur J; Smadja DM; Silvestre JS
    Stem Cells; 2014 Jan; 32(1):231-43. PubMed ID: 24105925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Debate: Are HIF Stabilizers a Viable Alternative to ESAs in the Management of Anemia in CKD? PRO.
    Singh AK
    Am J Nephrol; 2022; 53(5):361-365. PubMed ID: 35462362
    [No Abstract]   [Full Text] [Related]  

  • 52. New anemia therapies: translating novel strategies from bench to bedside.
    Macdougall IC
    Am J Kidney Dis; 2012 Mar; 59(3):444-51. PubMed ID: 22192713
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [(4-Hydroxyl-benzo[4,5]thieno[3,2-c]pyridine-3-carbonyl)-amino]-acetic acid derivatives; HIF prolyl 4-hydroxylase inhibitors as oral erythropoietin secretagogues.
    Hong YR; Kim HT; Lee SC; Ro S; Cho JM; Kim IS; Jung YH
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5953-7. PubMed ID: 24042008
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
    Raja R; Bloom E; Johnson R; Goldstein M
    Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Managing erythropoietin hyporesponsiveness.
    Kwack C; Balakrishnan VS
    Semin Dial; 2006; 19(2):146-51. PubMed ID: 16551293
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Renal anemia: from incurable to curable.
    Sato Y; Yanagita M
    Am J Physiol Renal Physiol; 2013 Nov; 305(9):F1239-48. PubMed ID: 23884144
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
    Flamme I; Oehme F; Ellinghaus P; Jeske M; Keldenich J; Thuss U
    PLoS One; 2014; 9(11):e111838. PubMed ID: 25392999
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Physiologic basis for the pharmacologic use of recombinant human erythropoietin in surgery and cancer treatment.
    Adamson JW; Spivak JL
    Surgery; 1994 Jan; 115(1):7-15. PubMed ID: 8284765
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
    Wu Y; Jiang Z; Li Z; Gu J; You Q; Zhang X
    J Med Chem; 2018 Jun; 61(12):5332-5349. PubMed ID: 29856623
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Erythropoietin and anemia.
    Tong EM; Nissenson AR
    Semin Nephrol; 2001 Mar; 21(2):190-203. PubMed ID: 11245780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.